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ABSTRACT 
 
 Streptococcus agalactiae, otherwise known as Group B Streptococcus (GBS), is a 
zoonotic, Gram-positive, commensal and invasive bacteria which is the leading cause of 
neonatal bacterial infections. These bacterial infections include sepsis, meningitis, 
pneumonia, and bacteremia. In neonates, GBS is most commonly transferred to the child 
in utero or during birth when the child aspirates amniotic or vaginal fluids. GBS can also 
infect the child through the bloodstream while in utero, causing premature births or still 
births. Children who survive the initial infection develop severe morbidities which 
include mental retardation, cerebral palsy, and seizures. GBS can also affect 
immunocompromised adults, leading to urinary tract infections, skin, and soft tissue 
infections, bacteremia, pneumonia, arthritis, and endocarditis. While there are current 
antibiotic methods of treatment, these treatments can lead to drug resistance. Therefore, 
other methods for treating GBS infections are desired. In this research project, creating a 
GBS CpsA double mutant in the LytR extracellular domain was attempted to determine 
how the double mutant affects capsule production. Formation of the CpsA double mutant 
was difficult and confirmation that the mutant is the correct sequence was not reached. In 
the future, the double mutant will be sequenced to determine the amino acid sequence of 
CpsA with alterations in the correct sequence. Then, this strain will be utilized to 
determine the role of these specific residues on GBS capsule level through an ELISA and 
morphology assays, and virulence will be measured through a zebrafish systemic 
infection.  
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INTRODUCTION 
 
 Microbial infections are a complicated series of dynamic interactions between the 
pathogen and its host (Phelps & Neely, 2005). The dynamic interplay between the host 
and the pathogen determines the outcome of the infections (Miller & Neely, 2004). The 
use of an animal model to study host-pathogen interactions where the response of both 
the host and the pathogen can be analyzed is vital to understanding virulence regulation 
and pathogenesis (Miller & Neely, 2004). In this study, a double mutant was generated in 
the amino acid sequence of the LytR domain of the CpsA protein in Streptococcus 
agalactiae, a pathogen infecting both neonates and adult throughout the world. The goal 
of the experiment was to alter the biochemical interactions of the CpsA LytR region, 
causing a decrease in the major virulence factor for S. agalactiae, the capsule. Once the 
CpsA mutant was correctly sequenced, a zebrafish model could be used to visualize the 
decrease in virulence due to an impairment in capsule production.  
Group B Streptococcus 
 S. agalactiae, otherwise known as Group B Streptococcus (GBS), emerged as a 
major cause of bovine mastitis in 1887(Emaneini, khoramian, et al., 2016). By 1970, 
GBS had emerged as a major cause of neonatal meningitis and sepsis (Emaneini, 
khoramian, et al., 2016). Today, GBS is recognized as a major public health problem 
causing invasive and non-invasive infections in pregnant and non-pregnant adults, 
especially the elderly and immunocompromised (Di Renzo et al., 2015; Dutra et al., 
2014). Non-pregnant adults have become increasingly associated with mortality due to 
invasive infections ( Dutra et al., 2014). GBS is a nonmotile, Gram-positive, β-hemolytic, 
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normal constituent of the microbiome as well as a common commensal of the 
gastrointestinal tract and genitourinary tracts of both males and females (Di Renzo et al., 
2015; Dutra et al., 2014; Lamagni et al., 2013; Landwehr-Kenzel & Henneke, 2014; 
Vornhagen, Adams Waldorf, & Rajagopal, 2017). While colonization can be transient, 
intermittent or persistent and is usually asymptomatic, colonization during pregnancy 
increases the risk of premature delivery and perinatal transmission through ascending 
infection during birth when the neonate aspirates contaminated amniotic or vaginal fluids 
(Emaneini, Jabalameli, Mirsalehian, Ghasemi, & Beigverdi, 2016). Once the commensal 
has moved from the vagina, through the cervix and into the uterus, the fetus can aspirate 
GBS, allowing the bacteria to invade the lung, then enter the bloodstream until finally 
crossing the blood brain barrier (BBB) (Figure 1) (Rajagopal, 2009; Vornhagen et al., 
2017). This pathway leads first to pneumonia, then sepsis and finally meningitis 
(Rajagopal, 2009).   
Figure 1: Proposed mechanism for GBS infection in-utero. (A) GBS is a commensal of the genital tract. 
(B) GBS infiltrated the uterus in pregnant women who are asymptomatic carriers. (C) The neonate aspirates 
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GBS during birth. (D) GBS enters the lung causing pneumonia. (E) GBS gains access to the bloodstream 
causing sepsis. (F) GBS invades the blood brain barrier causing meningitis. (Rajagopal, 2009).  
  
 Invasion of GBS to the amniotic cavity can cause inflammation of the placental 
membranes (chorioamnionitis), leading to premature births and still births(Vornhagen et 
al., 2017). GBS infections can lead to early on-set disease (EOD) and late on-set disease 
(LOD) in the neonate. EOD is caused by exposure to GBS before or during the birthing 
process and is characterized by pneumonia or sepsis occurring within the first 6 days post 
birth (Emaneini, Jabalameli, et al., 2016; Maisey, Doran, & Nizet, 2008). LOD is a 
bloodstream infection characterized as meningitis and bacteremia within 7-90 days post 
birth (Emaneini, Jabalameli, et al., 2016; Rajagopal, 2009). Non-pregnant adults 
clinically manifest GBS invasive infections in a variety of conditions which include skin, 
soft tissue and urinary tract infections, bacteremia, pneumonia, arthritis and endocarditis 
(Rajagopal, 2009). Meningitis and most neonatal infections are most frequently linked to 
the type III serotype of GBS (Di Renzo et al., 2015). Morbidity in survivors is high and 
includes neurological sequelae, cortical blindness, deafness, uncontrolled seizures, 
hydrocephalus, hearing loss, and speech and language delays (Johri et al., 2006; 
Simonsen, Anderson-Berry, Delair, & Davies, 2014).  
 In 1996, the CDC introduced intrapartum antibiotic prophylaxis (IAP) as the 
method of reducing the risk of neonatal morbidity and mortality from invasive infection 
(Braye et al., 2018; Phares et al., 2008). The regimen of IAP begins with a pregnant 
woman in labor receiving penicillin or ampicillin continuously for four hours until 
delivery (Powers & Wirtschafter, 2010). If the mother is allergic to penicillin, a variety of 
antibiotics can be offered; cefazolin or clindamycin is administered continuously for 
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eight hours until delivery, erythromycin is administered continuously for six hours until 
delivery, or vancomycin is administered continuously for twelve hours until delivery 
(Powers & Wirtschafter, 2010). Due to 46% of serotypes being resistant to erythromycin, 
the CDC no longer recommends erythromycin as an acceptable alternative for IAP (Stoll 
et al., 2011; Verani, McGee, & Schrag, 2010). The goal of IAP is to achieve adequate 
levels of antibiotic in fetal circulation without achieving neurotoxic serum levels (Braye 
et al., 2018). The use of IAP has resulted in a substantial decline in EOD, but has not had 
the same effect on LOD or infections in non-pregnant adults (Phares et al., 2008; 
Schuchat, 1999). The risks of IAP include drug resistance, adverse maternal reactions, a 
potential increase in Gram-negative infections in preterm neonates, and a lack of 
knowledge on the long term effects on the microbial balance of the mother and the 
neonate(Braye et al., 2018; Simonsen et al., 2014). Alternative methods of treatment for 
GBS infections such as a chlorhexidine douche and pretreatment with probiotic 
lactobacillus species have shown limited success, but IAP is still the best method of 
treating EOD (Braye et al., 2018; Vornhagen et al., 2017). 
 World-Wide Incidence, Screening, and Serotypes 
 From 1995-2005, incidence of EOD in the United States remained the same while 
incidences of LOD and non-pregnant related disease increased (Lamagni et al., 2013; 
Phares et al., 2008). From 1991-2010, EOD, LOD, and non-pregnant related disease in 
England and Wales increased (Lamagni et al., 2013). From 2010-2011, incidence of LOD 
were significantly higher in the United Kingdom and Ireland than incidence of EOD with 
LOD exhibiting a correlation of low gestational age and low birth rate (Okike et al., 
2014). In contrast, many developing countries exhibit a lack of significant clinical disease 
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due to GBS (Johri et al., 2006; Schuchat, 1999). This is puzzling, but can be explained 
through the commonality of less invasive procedures at hospitals, at home births, and less 
virulent strains being prevalent (Johri et al., 2006; Schuchat, 1999). The less invasive 
procedures could be limiting the risk of GBS infection while at home births increase the 
risk of death due to GBS infection, masking the detection of EOD (Johri et al., 2006; 
Schuchat, 1999). The apparent lack of invasive disease in developing countries as well as 
excluding GBS invasive infections, which cause spontaneous abortion or stillbirth from 
the incidence reports makes it difficult to determine the true incidence of GBS invasive 
infection throughout the world (Lamagni et al., 2013).  
 In the United States, the Center for Disease Control (CDC) recommends a 
universal screening approach which requires that all women receive vaginal and anal 
swabs at 35-37 weeks gestations and cultured to determine positive colonization (Verani 
et al., 2010). This approach is also used in Italy, Spain, France, Germany, Switzerland, 
Czech Republic, Belgium, and Poland (Rodriguez-Granger et al., 2012). In Europe, the 
risk-factor based screening approach is recommended due to the countries beliefs that 
their low national incidence will not decrease further and that introduction of universal 
screening will increase antimicrobial resistance and anaphylactic reactions (Di Renzo et 
al., 2015). This approach required use of IAP when a pregnant woman presents with 
labor at less than 37 weeks, a release of membranes for more than 18 hours, and a fever 
of more than 38.0°C. This approach is also used in the Netherlands, New Zealand, and 
Australia.  
 There are pros and cons to each approach, with the universal approach missing 
pre-term babies as well as causing false positives and negatives due to the transient nature 
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of GBS (Braye et al., 2018). The risk factor based approach does not address the risk of 
ascending infection and can lead to sub-optimal administration of IAP due to time used 
identifying the risk factors and administering the antibiotics (Braye et al., 2018; 
Vornhagen et al., 2017). Neither approach prevents LOD infections where vertical 
transmission is not the only mode of acquisition (Vornhagen et al., 2017). To combat the 
weaknesses of these approaches, point of care test for at birth through rapid real time 
PCR assays can be used to detect GBS colonization (Di Renzo et al., 2015). This method 
is advantageous for determining GBS colonization in preterm deliveries  and decreasing 
the number of false positive or negative cultures, but does not allow antibiotic 
susceptibility testing and can be expensive (Di Renzo et al., 2015). A screening protocol 
which could be applied throughout the world may help maintain low percentages of 
EOD.  
 One of the world’s many ongoing public health challenges is to develop vaccines 
that are effective against all serotypes of the infectious disease Group B Streptococcus 
(GBS) (Johri et al., 2006). This is increasingly difficult because most vaccines are 
serotype specific and the ten serotypes vary throughout the world. The least common 
serotypes are VI, VIII, IV, and Ib. Serotypes VI and VIII are only predominant in Japan 
and serotype Ib is only predominant in the Netherlands while serotype IV is predominant 
in the both the United Arab Emirates and Norway (De Francesco, Caracciolo, Gargiulo, 
& Manca, 2012; Emaneini, khoramian, et al., 2016; Powers & Wirtschafter, 2010; Rojo-
Bezares et al., 2016). Serotypes Ia, III, and V are arguably more predominant throughout 
the world. Serotype V is predominant in Italy, Lebanon and Gambia (De Francesco et al., 
2012; Emaneini, Jabalameli, et al., 2016; Powers & Wirtschafter, 2010). Serotype Ia is 
7 
	
predominant in Brazil and Portugal while being linked to early onset disease (EOD) in 
the United States and the United Kingdom (Dutra et al., 2014; Otaguiri et al., 2013; 
Phares et al., 2008; Powers & Wirtschafter, 2010). Serotype III is predominant in Iran, 
Poland, Taiwan, England, Wales, and Spain while being linked to late-onset disease 
(LOD) in the United Stated and the United Kingdom(Emaneini, Jabalameli, et al., 2016; 
Emaneini, khoramian, et al., 2016; Lamagni et al., 2013; Phares et al., 2008; Powers & 
Wirtschafter, 2010; Rojo-Bezares et al., 2016). Erythromycin, clindamycin, and 
tetracycline resistance was common throughout the world with rates varying greatly 
among different countries (Emaneini, Jabalameli, et al., 2016). Resistance rates in the 
United States and Europe were much higher than rates in Iran and Brazil, reflecting 
differences in doses, public health policies, and the spread of particular clones (Emaneini, 
Jabalameli, et al., 2016; Otaguiri et al., 2013). Despite claims that penicillin non-
susceptible GBS have been reported in the US and Japan, all serotypes mentioned in all 
parts of the world reported susceptibility to penicillin (De Francesco et al., 2012; Dutra et 
al., 2014; Emaneini, Jabalameli, et al., 2016; Lamagni et al., 2013; Phares et al., 2008) 
Because of the wide variety in predominant serotypes and the increases in antibiotic 
resistance throughout the world, the goal of research today is to exploit the GBS genomic 
sequences to establish a universally effective vaccine and eliminate the need for 
antibiotics (Johri et al., 2006).  
Virulence and Pathogenesis of S. agalactiae 
 Group B Streptococcus virulence is complex and multifactorial with several 
virulence factors involved in the adhesion to and invasion of the host cells as well as 
evading the immune system of the host (Dutra et al., 2014). These virulence factors are 
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regulated through expression of signal transduction systems (STS) in response to the 
external environment (Rajagopal, 2009). Virulence factors include α/β antigens of the C 
protein, surface protein Rib, hyaluronate lyase, C5α peptidase, laminin binding protein 
(LMB) and pilus proteins (Di Renzo et al., 2015; Dutra et al., 2014; Emaneini, 
khoramian, et al., 2016).  Cα proteins mediates adherence to epithelial cells while Cβ 
proteins participate in invasion and resistance to phagocyte clearance (Emaneini, 
khoramian, et al., 2016; Johri et al., 2006). Resistance to proteases (Rib) is used to confer 
protective immunity and has been linked to almost all strains of type III that caused 
invasive infections in neonates(Emaneini, khoramian, et al., 2016; Johri et al., 2006). 
Hyaluronate lyase surface proteins cleave hyaluronan and facilitates the invasion and 
spreading of GBS through the host tissues (Emaneini, khoramian, et al., 2016). C5α 
peptidase is a surface localized serine protease which cleaves a component of the human 
complement system C5α, leading to reduced neutrophil chemotaxis and decreased 
opsonophagocytic killing (Emaneini, khoramian, et al., 2016; Johri et al., 2006). Laminin 
binding proteins are important to GBS translocation across the interstitial epithelial cells 
and the blood brain barrier (BBB) (Landwehr-Kenzel & Henneke, 2014). Pilus proteins 
are involved in the adhesion by promoting colonization of the epithelial cell surfaces 
which supports biofilm formation and facilitates translocation across the BBB 
(Landwehr-Kenzel & Henneke, 2014).  
 The most important virulence factor of GBS is the capsular polysaccharide (CPS) 
which acts as the outer most layer of the cell surface, provides additional protection from 
extracellular assaults, and helps bacterial invasion by interfering with phagocytic 
clearance (Di Renzo et al., 2015; Hanson & Neely, 2012). Interfering with the phagocytic 
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clearance allows for GBS to disseminate through the blood-stream (Hanson et al., 2012). 
Capsular polysaccharides have differences in structure on the surface polysaccharide that 
enables the subdivision into 10 serotypes and are important targets for the development 
of vaccines (Dutra et al., 2014; Emaneini, Jabalameli, et al., 2016). Disturbances of the 
CPS can result in pleiotropic effects that highlight the interdependence of each 
component to the overall function of the cell surface (Hanson & Neely, 2012).   
 Pathogenesis of GBS can first be traced to asymptomatic mucosal colonization by 
adherence and invasion of the  host-cell surface through initial binding to the 
extracellular cell matrix (ECM) by adhesion factors such as fibrinogen, fibronectin, and 
laminin (Landwehr-Kenzel & Henneke, 2014; Maisey et al., 2008; Rajagopal, 2009). 
GBS may prevent adaptive immune responses at sites of colonization through limiting 
cyclic dinucleotide secretion at the mucosal epithelium (McFarland & Woodward, 2016). 
The cell surfaces of Gram-positive pathogens are composed of a single cell membrane 
and represents a complex association of glycopolymers that control cell division, 
homeostasis, immune evasion, tissue invasion and resistance to antimicrobials (Hanson & 
Neely, 2012). As evident in Figure 2, the glycopolymers of the phospholipid bilayer 
include peptidoglycan cell wall, wall teichoic acids, lipoteichoic acids, and the major 
virulence factor capsular polysaccharides (Di Renzo et al., 2015; Hanson & Neely, 2012).  
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Figure 2: Simplified model of the cell surface of Gram-positive bacteria: lipid membrane (LM), 
peptidoglycan (PG), lipoteichoic acids (LTA), wall teichoic acids (WTA), capsular polysaccharide (CPS). 
(Hanson & Neely, 2012).  
 The thick peptidoglycan layer (PG) protects the membrane and acts as a scaffold 
for other components of the cell membrane (Hanson & Neely, 2012). Anionic teichoic 
molecules are interspersed through the PG, providing the cell wall integrity, are useful for 
the invasion of the host tissue, are useful for the regulation of cell division, and supplying 
the major portion of the overall negative charge (Hanson & Neely, 2012). These include 
the lipoteichoic acids (LTA) and the wall teichoic acids (WTA). The WTA is covalently 
linked to the N-acetylmuramic acid (NAM) structure of the PG while LTA is anchored to 
the membrane through a glycolipid (Hanson & Neely, 2012). Capsule polysaccharides 
(CPS), an important virulence factor, are essential for systemic dissemination during 
infection  (Hanson, Lowe, & Neely, 2011). Regulation of the CPS is vital for bacteria to 
act as a commensal and a pathogen (Rowe et al., 2015). GBS CPS is attached to the N-
acetylglucosamine (NAG) of the PG (Hanson & Neely, 2012). The connections of WTA 
and CPS to the PG are important to the final cell architecture and essential for proper cell 
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wall functionality (Kawai et al., 2011). Because high levels of CPS inhibit adherence, 
GBS may facilitate alterations in the cell surface from CPS and immune evasions 
functions to WTA and LTA adherence and colonization functions through signals from 
the host (Hanson et al., 2011; Hanson & Neely, 2012). Following adherence and 
colonization, GBS can use invasions to promote bacterial entry and survival within host 
cells (Maisey et al., 2008). Intracellular uptake of GBS by alveolar epithelial and 
pulmonary endothelial cells involves activation of cytoskeletal rearrangements in the 
target cell through Rho family GTPases (Maisey et al., 2008). CPS prevents uptake and 
clearance by macrophages and neutrophil through preventing opsonophagocytic killing 
(Maisey et al., 2008).  
CpsA 
 In Gram-positive bacteria, such as GBS, the CPS is covalently attached to the cell 
wall PG with members of the LtyR-Cps2A-Psr (LCP) family (Eberhardt et al., 2012). 
LCP are phosphotransferase enzymes used to catalyze the transfer of anionic cell wall 
polymers like capsular polysaccharide and teichoic acids from lipid-linked polymers to 
PG (Eberhardt et al., 2012). The LCP family has a role in the biogenesis of WTA and 
anionic polysaccharides as well as the maintenance of cell envelopes (Kawai et al., 2011; 
Rowe et al., 2015). Members of the LCP contribute to the maintenance of normal capsule 
levels  and the retention of CPS to the cell wall (Eberhardt et al., 2012). CpsA is believed 
to act as the enzyme responsible for the attachment of CPS to the cell wall, direct the 
polymerization and export of the polysaccharide, or be involved in transcriptional 
regulation (Hanson et al., 2011; Rosini et al., 2015; Toniolo et al., 2015). CpsA exhibits 
the predicted topology exhibited in Figure 3 where there are three transmembrane 
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domains and two extracellular domains which include the accessory domain and the LytR 
domain (Hanson et al., 2011). The accessory domain is specific to CpsA while the LytR 
domain is a shared domain among pathogenic bacteria including Bacillus subtilis 
(Hanson et al., 2012). LytR proteins have been associated with transcriptional attenuation 
of the lytRABC divergon which is believed to encode cell-wall modifying enzymes as 
well as potentially alter the function of the extracellular  DNA polymerase processivity 
factor (DNA_PPF) domain (Hanson et al., 2012). The DNA-PPF is adjacent to the LytR 
domain and used in protein-protein interactions (Hanson et al., 2012). In contrast, the 
leucine zipper domain extends from the cytoplasmic regions into the transmembrane 
regions and is used in DNA binding and dimerization (Hanson et al., 2011).  
	Figure 3: Diagram of the topology of cpsA. 	
 As shown in Figure 3, CpsA is composed of a short N-terminal cytoplasmic tail, a 
small extracellular loop, a small cytoplasmic loop, and a large extracellular C-terminus 
(Hanson et al., 2011). The unique topology of CpsA suggests a novel mechanism of 
transcriptional regulation (Hanson et al., 2011). CpsA is the first gene in the CPS operon 
and acts as a cell-surface protease that cleaves the EMC protein fibrinogen, producing 
adherent fibrin like cleavage products which coat the bacterial surface and interfere with 
complement-mediated clearance (Hanson et al., 2011; Maisey et al., 2008; Rajagopal, 
	
accessory	domain	 LytR	domain	membrane	
Leucine	zipper	
motif	
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2009). Sequence analysis of the cytoplasmic regions highlight the high density of 
positively charged amino acids, indicating that CpsA may be able to bind directly to the 
negatively charged phosphate backbone of DNA (Hanson et al., 2011). CpsA regulates 
capsule expression and is adjacent to the putative capsule promotor (Hanson et al., 2011). 
Experiments completed on the CpsA regions have indicated that the full CpsA region 
must be present for full expression of the capsule, mutation in cpsA lead to unusually 
long chains of cocci, the large extracellular region and the cytoplasmic loops of CpsA 
affect the specificity with which CpsA can interact with DNA sequences, and the N-
terminus represented in Figure 3 is required for binding to DNA  (Eberhardt et al., 2012; 
Hanson et al., 2012; Rowe et al., 2015).  
 To obtain insights into the LCP family of proteins and their likely enzymatic 
functions, Kawai et al. determined the crystal structure of the CpsA region of S. 
pneumoniae.  
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Figure 4: The crystal structure of S. pneumoniae CpsA. The purple region is the accessory domain, the 
green region represents the LytR domain, and the small yellow region represents the phospholipid. (Kawai 
et al, 2011) 
  
 As shown in Figure 4, the LCP domain has an α-β-α architecture  with a 5-
stranded β-sheet forming the core of the protein and alpha helices and two pairs of β-
strands extending away from the protein core, forming the interface between the two 
domains (Kawai et al., 2011). Kawai et al., concluded that the accessory domain folded 
independently of the LCP domain, indicating separate functions for the two regions 
(Kawai et al., 2011). A polyisoproenoid phosphate lipid was located in the hydrophobic 
pocket between the β-sheet and α-helices (Kawai et al., 2011).  
Figure 5: Diagram of lipid binding in the LCP domain with A, B showing decaprenyl-phosphate binding 
and C, D representing octaprenyl-pyrophosphatase binding. Amino acids of interest are R374 and Q378. 
(Kawai et al., 2011) 
 
 The polyisoproenoid phosphate lipid, shown in Figure 5, is lined with 
hydrophobic side chains from residues that are completely conserved in hydrophobic 
character across the entire LCP family of proteins (Kawai et al., 2011). Key interactions 
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between the lipid and the protein are maintained in both structures (Kawai et al., 2011). 
Because deletion of the CpsA gene as well as deletion of the LytR domain have both 
been associated with a decrease in capsule production (Hanson et al., 2012), it was 
hypothesized that mutations in key amino acids of the LytR domain from Figure 5, 
specifically R374 and Q378, would lead to a decrease in capsule production.  
Zebrafish as a Model Organism 
 Animal models are vital to understanding virulence regulation and host-pathogen 
interactions in the study of bacterial pathogenesis in vivo. In recent years, a need for an 
alternative vertebrate model for studying bacterial infections has arisen and been filled by 
the zebrafish (Danio Rerio). The zebrafish has been used to study both aquatic and 
human bacterial pathogens which include but are not limited to Salmonella arisonae, 
Bacillus subtillis, and Streptococcus agalactiae (Kim et al., 2015; Phelps & Neely, 2005). 
Zebrafish have several advantages for use as a model organism. Firstly, this model is 
inexpensive, easy to maintain, store, and genetically manipulate, and produce an 
abundance of offspring (Phelps & Neely, 2005; Trede, Langenau, Traver, Look, & Zon, 
2004).  For decades, murine models were an ideal model for bacterial pathogenesis, but 
with the advent of target gene knockouts became too difficult, expensive, and time 
consuming to use (Miller & Neely, 2004). Compared to the murine model, zebrafish can 
provide a more natural route of infection for the invasion of a pathogen in the brain. 
(Phelps & Neely, 2005). The small size of zebrafish is beneficial for studying disease 
progression because a longitudinal section of the whole adult zebrafish can be mounted 
on a slide and used for histological analysis (Phelps & Neely, 2005). Additionally, 
zebrafish possess a fully developed immune system which can replicate the host-
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pathogen responses in humans and allows for the study of diseases that involve both 
systems (Miller & Neely, 2004; Phelps & Neely, 2005). The innate immune system, with 
a primary function of eliminating invading pathogens and initiating the adaptive immune 
system, may be the most rapid and efficient in responding to microbial exposure (Phelps 
& Neely, 2005; Trede et al., 2004). The adaptive immune system development is delayed, 
allowing for stepwise infection and study of specific innate and adaptive immune 
responses (Phelps & Neely, 2005). Lastly, the transparency of zebrafish for their first 
week of life allows for observation of developmental processes in real time through 
fluorescently labeled bacteria (Kim et al., 2015; Miller & Neely, 2004; Phelps & Neely, 
2005). This technique was used to study early T cell development in a living organism 
(Trede et al., 2004). As a vertebrate genetic model, the zebrafish has proven itself as an 
alternative for the study of genetic modifiers to the immune response (Trede et al., 2004).  
 Zebrafish were established as being susceptible to Streptococcus iniae, leading to 
the 16S rRNA sequence of the bacteria revealing close genetic relation between S. iniae 
and S. agalactiae (Miller & Neely, 2004). S. agalactiae, the human-specific pathogen is 
characterized by sepsis after intravascular invasion (Miller & Neely, 2004). Similar to S. 
agalactiae, S. iniae cause systemic infections which disseminate into multiple organs 
including the heart, liver, and brain and rely on genes involved in β-hemolysis and 
capsule synthesis for virulence (Miller & Neely, 2004).   
 Zebrafish have emerged as a valuable tool for modeling S. agalactiae infections 
in both the adult and larvae (Kim et al., 2015). Adult zebrafish exhibit mortality, cerebral 
edema and bacteria in the brain while the larvae show susceptibility through bacteria 
crossing the blood brain barrier (BBB) and dose-dependent mortality (Kim et al., 2015). 
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Hanson et al., demonstrated that mutated strains with a CpsA deletion (∆CpsA) were not 
attenuated in human whole blood, despite the production of less capsule, which lead to in 
vivo assessment of virulence (Hanson et al., 2012). Results showed WT strains of GBS 
were highly virulent with 8% survival while ∆CpsA strains were attenuated with 68% 
survival (Hanson et al., 2012). The observed decrease in virulence of ∆CpsA in zebrafish 
lead researchers to conclude that disruption of CpsA may lead to deficiencies that are 
only observable in the context of systemic disease (Hanson et al., 2012). Therefore, after 
the CpsA double mutant is constructed, attenuation of virulence should be tested in the 
context of systemic disease through analysis in a zebrafish model.  
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MATERIALS AND METHODS 
 Preparation of Plasmid: The plasmid pLZ12-rofA-pro (strain #12E34) was 
digested first with BamHI and allowed to incubate at 37°C for 15 minutes. Then the 
plasmid was digested with PstI and allowed to incubate at 37°C for 30 minutes. The 
digested plasmid was separated on an 0.8% agarose gel to check for a band at 4500 bp 
and isolated from the gel using the GeneJet Gel Extraction Kit (Thermo-Fisher).    
 Polymerase Chain Reactions (PCR): S. agalactiae genomic DNA was used as a 
template to amplify regions of the DNA associated with the cpsA gene. The polymerase 
utilized was Q5 (New England Biolabs), a high-fidelity polymerase and the primers used 
were specific to each reaction. The long fragment reaction used primers 5’ GBS-CpsA-
RBS-BamHI and 3’ GBS-cpsA-Q382A/ R378A (#1740, #1956) while the short fragment 
reaction used primers 3’ GBS-cpsA-full-PstI and 5’ CpsA-Q382/R378 (#1672, #1955).  
After PCR was completed at an annealing temperature of 63°C, both reactions were 
separated on an 0.8% agarose gel, to confirm DNA fragments of 1160 bp and 338 bp. 
The reactions were gel purified using the GeneJet Gel Extraction Kit (Thermo-Fisher).  
 PCR Splice Overlap Extension (SOE): The two PCR fragments were used as a 
template to SOE the fragments together, forming a full-sized fragment of ~1475 bp. The 
polymerase utilized was Q5 (New England Biolabs) and the two primers used were 5’ 
GBS-CpsA-RBS-BamHI and 3’ GBS-cpsA-full-PstI (#1740, #1672) at an annealing 
temperature of 65°C. The reaction was separated on an 0.8% agarose gel to confirm a 
final product of 1475 bp. The full-sized fragment was gel purified using the GeneJet Gel 
Extraction Kit (Thermo-Fisher) followed by a digestion with BamHI and PstI.  
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Figure 6: PCR SOEing model. The CpsA gene represented at the top will have mutations occur at the 
double arrows labeled 1. Reaction 1 and reaction 2 will SOE together at sight 1, forming the completed 
fragment represented in reaction 3. Under Gel Electrophoresis, a band will be visible at ~1475 bp.  
 
 Ligation: In a 1.5 mL microcentrifuge tube, the digested pLZ12-rofA-pro plasmid 
was utilized as the vector backbone. The digested PCR SOEing fragment was inserted 
into the plasmid with the assistance of the T4 DNA ligase (New England Biolabs). The 
reaction was incubated at room temperature for 30 minutes. To inactivate the ligase, the 
reaction was incubated at 65°C for 10 minutes, followed by a butanol precipitation to 
remove excess salts.  
 Transformation into E.coli: The DNA ligation mixture was mixed with electro 
competent cells and transferred to a cold electroporation cuvette. The cells were 
electroporated with a Gene Pulser (Bio-Rad) set to 25 µF, 2.5 kV, and 200 Ω. The 
electroporated cells were immediately transferred to SOC medium and incubated at 37°C 
for 90 minutes with continual shaking. Cells were then plated onto Luria-Bertani (LB) 
agar plates supplemented with chloramphenicol at 20 µg/ml final concentration and 
1	
1956	
1955	à	
Transs	
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incubated at 37°C overnight. A PCR on the colonies was performed to confirm that the 
PCR SOEing fragment was inserted into the E.coli. 
  Plasmid Isolation: In a 250 mL Erlenmeyer flask, 100 mL of (LB) medium 
supplemented with 20 µg/ml chloramphenicol was used to culture several positive 
colonies post transformation. Overnight, the cultures incubated at 37°C with continual 
shaking. Next day, a PureLink HiPure Plasmid Filter DNA Purification Kit (Invitrogen) 
was used to purify plasmid DNA. Then, an Isopropanol Precipitation was performed, and 
a Nanodrop was used to determine the concentration of DNA present.  
 Sequencing Prep: Three PCR reactions were run on plasmid prep colonies with 
good DNA concentrations before the CpsA double mutant was sequenced. DreamTaq 
Mastermix was combined in 0.2 mL microcentrifuge tubes with different primers per 
reaction and annealed at a temperature set to 55°C. The expected band size was 350 bp 
for Set A, 720 bp for Set B, and 700 bp for Set C.   
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RESULTS 
 Preparation of Plasmid: The pLZ12-rofA-pro plasmid was double digested using 
the restriction enzymes BamHI and PstI. To confirm that the digested plasmid was cut 
correctly, the digest was separated on an 0.8% agarose gel by electrophoresis. The results 
visualized a fragment at band size ~4500 bp, as expected (Figure 7). The fragment was 
then gel isolated and later utilized during the ligation.  
Figure 7: Gel Electrophoresis of plasmid exhibits correct band size. The first column of the 0.8% 
agarose gel is the ladder while the third column in the digested plasmid. A faint band is visible at the 
expected bp of ~4500.  
 
 PCR: Genomic DNA was used as the template in 2 PCR reactions. Reaction 1 
used primers 5’GBS-CpsA-RBS-BamHI and 3’ CpsA-Q382/R378. Reaction 2 used 
primers 5’GBS-CpsA-Q382/R378 and 3’GBS-CpsA-full-PstI. Following PCR, the 
fragments were separated by electrophoresis 0.8 % agarose gel. The results visualized the 
bands at bp ~1160 for reaction 1 and ~338 for reaction 2, as expected for each reaction 
(Figure 8). The fragments were gel purified and used in the PCR SOE.  
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Figure 8: Gel Electrophoresis shows correct PCR band size. The first column represents the ladder. The 
third column shows the band for reaction 1, with the expected band size at ~1160 bp. The fourth column 
shows the band for reaction 2, with the expected band size at ~338 bp. Reaction 2 has a second band which 
indicated potential contamination, so this reaction was completed again.  
 
 PCR SOE: The purified PCR fragments from reactions 1 and 2 were used as the 
template with the outside primers in a PCR SOEing reaction to form a full-sized 
fragment. To confirm that a single full-size fragment was generated, the reaction was 
separated by electrophoresis on an 0.8% agarose gel. The results visualized the band at 
~1475 bp, as expected (Figure 9). The fragment was gel isolated and digested using 
BamHI and PstI to prepare the fragment for ligation.   
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Figure 9: Gel Electrophoresis of PCR SOE shows correct band size. Starting from the left, the first 
column is the ladder and the third column is the PCR SOEing reaction. The band size at ~1475 bp is the 
correct band size for the reaction.  
  
 Transformation: The digested PCR SOEing reaction and the digested pLZ12-
rofA-pro plasmid were ligated together, butanol precipitated and transformed into 
competent E.coli by electroporation. Transformants were then selected on LB-
chloramphenicol agar plates. Any number between 1 and 1000 colonies could develop on 
these plates (Figure 10A). To purify the colonies, individual colonies were streaked onto 
a new LB-chloramphenicol agar plate with 8 colonies per plate and grown overnight 
(Figure 10B). The purified colonies were utilized in the colony PCR.  
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      A 
                                                                    B                                                                  
Figure 10: LB cam20 plates show colony growth and purification. In 10A, the transformations were 
plated at 50 µl, 150 µl, and 800 µl. After incubating overnight at 37°C, colonies were purified using the 
‘pizza plate’ as shown in 10B. Individual growths were streaked onto a plate, forming a pizza shape and 
were later used to PCR the colonies.  
  
 Colony PCR: To confirm that the cpsA gene was present on the plasmid in E.coli, 
colony PCR was performed and using primers specific for the cpsA gene and reactions 
were separated by electrophoresis on an 0.8% agarose gel. The results visualized the band 
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at ~1475 for positive colonies as expected (Figure 11). Negative colonies had no band 
present. Positive colonies were prepared for sequencing.  
Figure 11: Gel Electrophoresis of Colony PCR shows positive colony. Starting from the left, columns 
are organized as followed: ladder, positive control (genomic DNA), negative control (ddH2O), and 
colonies. The positive control PCR was ineffective because no band is present. The negative control looks 
as expected with no band. The colonies all appear negative except for column 8. With a band at ~1475bp, 
this colony is positive and was prepared for sequencing.  
 
 Sequencing Prep: After plasmids were purified from the positive transformants, 
an additional PCR was performed with the primers that were to be used for sequencing. 
Three sets of PCRs were performed with 5 primers and reactions were visualized on an 
0.8% agarose gel. The bands for set B and C were visualized as expected at ~720 bp and 
~700 bp respectively (Figure 12, column 6, and 9). Set A visualized 2 bands, one at the 
expected ~350 and another at ~700 bp (Figure 12, column 3). This second band indicated 
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that sequencing the CpsA double mutant would result in an incorrect sequence, so the 
mutant was not sequenced. The project was begun again from scratch because there was 
not enough PCR SOEing reaction to complete a new ligation.  
Figure 12: Gel Electrophoresis of Sequence Prep PCR indicated that the mutant has the incorrect 
sequence. Starting from the left, the first column is the ladder, the third column is Set A, the fifth column is 
Set B, and the seventh column is Set C. Set B and C visualize expected bands at ~720 bp and ~700 bp 
respectively. Set A visualized 2 bands, one at ~350 bp, as expected, and a second band at ~700 bp. This 
second band indicates that the CpsA double mutant sequence will be incorrect.  
 
 Construction of the CpsA Double Mutant: Construction of the CpsA double 
mutant began by preparing the plasmid. The pLZ12-rof-A pro plasmid was double 
digested correctly, as shown in Figure 7. This step presented with no major 
complications. The next step involved creating 2 PCR reactions. Reaction 1 had no major 
complications when forming the reaction while reaction 2 presented with a correct band 
at ~338bp and an incorrect band at ~1500bp as visualized in Figure 8. Therefore, PCR 
reaction 2 was attempted again with the correct band at ~338 bp being the only band 
visualized. Both fragments were gel purified and used in the PCR SOEing reaction 
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presented in Figure 9. The PCR SOEing reaction generated a full-size fragment from 
reaction 1 and 2 with no major complications. The full-size fragment was then gel 
isolated and digested with BamHI and PstI to prepare the fragment for ligation.  
 The plasmid and the PCR SOEing reaction were ligated together, butanol 
precipitated, transformed into competent E.coli, and plated onto LB-chloramphenicol 
agar plates as shown in Figure 10. The purified colonies were then used for colony PCR 
to confirm positive colonies. These steps took 6 weeks to complete because positive 
colonies were not identified through colony PCR. During the first round of ligation, 
electroporation, plating and colony PCR, no positive colonies were located despite 
hundreds of colonies being grown. Because a pellet is not visible during the 
electroporation step, it was assumed that the electroporation was not completed correctly. 
The electroporation, plating and colony PCR was completed three times more with no 
positive colonies resulting. It was then determined that the reason no positive colonies 
were visible was due to the ligation being performed incorrectly. Therefore, the ligation, 
electroporation, plating and colony PCR was again repeated. This round of plates showed 
growth on the negative control plate, but after counting it, was determined that the 
number of colonies grown on the negative control plate were less than the number of 
colonies grown on the positive plate. Therefore, a colony PCR was performed looking for 
positive colonies. The results of the colony PCR are expressed in Figure 11 with column 
8 representing a positive colony. Two positive colonies were found from these plates.  
 The plasmid DNA from the two positive colonies had the concentration of DNA 
examined using a Nanodrop. It was determined that one of the positive colonies did not 
have a high enough concentration of DNA present to sequence the cpsA gene 
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electroporated into E.coli. Therefore, only one colony was prepared for sequencing. The 
sequence preparation using primers that were going to be used during sequencing is 
shown in Figure 12. Three sets of PCR reactions were performed with Sets B and C 
shown in columns 6 and 9 visualizing the correct bands at ~720 bp and ~700 bp 
respectively. Set A presented in column 3 visualized the expected band at ~350 bp as 
well as an unexpected band at ~700bp. The second band at ~700bp indicated that the 
CpsA sequence would not be correct so the colony was not sequenced. It was determined 
that the plasmid was the most likely cause of the incorrect band. Moving forward, a new 
pLZ12-rofA-pro plasmid was used beginning at the ligation step.  
 When the ligation was attempted again, there was not enough PCR SOEing 
reaction to complete the ligation and there was also no more reaction 1 or reaction 2 
prepared to SOE together. Therefore, reaction 1 and 2 were re-prepared via PCR. After 
the PCR, both reactions were run on a gel with reaction 2 exhibiting the expected band at 
~338bp. Reaction 1 did not exhibit any band. Reaction 1 was again prepared through 
PCR and run on a gel with no band exhibited again. To correct for any potential 
contamination, the ddH2O was replaced and all primers were prepared with new water. 
Reaction 1, with the new ddH2O and the new primers, was prepared via PCR and run on 
a gel with no band present. After the water was replaced, the Q5 Polymerase and Buffer 
were both replaced. The PCR with the new Q5 was run twice with no band being present. 
Then, the dNTPs were re-made with the new ddH2O and PCR reaction 1 was again 
performed with the same no band result. The next step was to create more PCR SOEing 
using what was left of the original PCR SOEing reaction. This approach, when separated 
on a gel, again produced no band at ~1470bp. Then, the genomic DNA concentration was 
29 
	
tested through a Nanodrop and was determined to have good purity, indicating that the 
genomic DNA was not interfering in the PCR reaction. After the Nanodrop, the melting 
temperatures of 5’ GBS-CpsA-RBS-BamHI and 3’CpsA-Q382/R378 were double 
checked and it was discovered that the melting temperature of the 5’GBS-CpsA-BamHI 
was being prepared in the PCR machine at an annealing temperature that was too high. 
The reaction 1 was then prepared in the PCR at a lower annealing temperature. This again 
did not show a band at ~1470 bp. It was then determined that the issue was not the 
components of the PCR reaction but that the PCR machine was defective. The PCR 
machine was changed, and the reaction was prepared several times with a newer PCR 
machine with the same no band result. Despite the Nanodrop results of the genomic DNA 
being well within the expected range of purity, reaction 1 was prepared again using a new 
genomic chromosome as well as a new Q5 polymerase. This again resulted in no band 
being present when the reaction was separated on a gel. After nearly 2 months of the PCR 
reaction 1 not having a band present when the reaction was separated onto a gel, Dr. 
Neely attempted to prepare the PCR reaction and was successful. In response, the 0.5 
microliters of the original PCR SOEing remaining was used to successfully create more 
PCR SOEing.  
 The newly formed PCR SOEing reaction was digested with BamHI and PstI, 
separated on a gel, and gel isolated to purify. Once digested, the ligation with the new 
double digested pLZ12-rofA-pro plasmid was completed. The ligation was electroporated 
into E.coli, plated onto LB-chloramphenicol plates, and a colony PCR was performed. 
The results of the colony PCR showed a faint positive band. To confirm whether a 
positive colony was present or if the faint band was due to contamination, the apparent 
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positive colony was re-streaked onto a LB-chloramphenicol plate with the goal of 
performing a new colony PCR and separating the reaction on a gel with the hope of 
visualizing a band at ~1475 bp.  
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DISCUSSION 
 For millions of years, the bacterial pathogen S.agalactiae has survived as a 
commensal of the vaginal and gastrointestinal tracts. In recent years, Group B 
Streptococcus (GBS) had been established as a major cause of both bovine systemic 
infections, neonatal systemic infections and systemic infection in adults, especially the 
elderly and immunocompromised (Di Renzo et al., 2015). To prevent the spreading of 
GBS infections, pregnant women undergo universal screening and when positive for GBS 
colonization, intrapartum antibiotic prophylaxis (IAP) is administered ideally up to four 
hours before birth. Despite CDC recommendations, only 67% of pregnant-women who 
deliver term infants with GBS infections were screened and 81% of term infants with 
GBS infections were born to mothers who screened negative for GBS colonization 
(Braye et al., 2018). While a treatment does exist, the transient nature of the infection as 
well as the virulence factors designed evade the host immune system limit the 
effectiveness of the treatment, especially in late onset disease (LOD) and the elderly. The 
most common virulence factor, capsule polysaccharide (CPS) is a novel target for the 
treatment of GBS systemic infections. Analysis of CPS led to the discovery of five highly 
conserved genes of the capsule operon with CpsA being proposed as a transcriptional 
regulator of capsule. The crystal structure of the S. pneumoniae CpsA region was recently 
determined and revealed the amino acids R374 and Q378 as potential targets for creating 
a mutation in the LytR domain of CpsA to decrease capsule production. The construction 
of a double mutant in the R378 and Q382 regions of S.agalactiae was attempted and 
unfortunately not achieved. In the future, the double mutant will be correctly sequenced, 
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capsule level will be determined through an ELISA, and the zebrafish model will be used 
to determine whether virulence was attenuated due to a decrease in capsule production.     
FUTURE DIRECTIONS 
 If a band is present at ~1475 bp, a Nanodrop will be performed on the positive 
colony to confirm the concentration of DNA present in the colony. When the Nanodrop is 
complete, the colony will be sequence prepared using the 5 primers that will be used 
during sequencing. With bands present at ~350bp ,~720bp, and ~700bp, the CpsA will be 
sequenced to confirm the mutations were made and the rest of the sequence is correct. 
Once the sequence confirmed correct, the CpsA will be transformed into wild type GBS 
and ∆CpsA through electroporation, plated onto THY-chloramphenicol agar plates, and 
PCR to confirm the presence of the plasmid. Once the presence of plasmid has been 
confirmed, assays will be completed to determined capsule production.  
 The first assay completed will be and enzyme-linked immunosorbent assay 
(ELISA). An ELISA will detect capsule production through the highly specific anti-body 
antigen interaction. It is expected that the ∆CpsA strains will produce less capsule than 
the wild type strain, indicating that the antibody will detect less capsule. Once a decrease 
in capsule production has been confirmed, a colony morphology will be analyzed using 
microscopy to determine the length of cocci due to the capsule. Virulence will be 
measured through the number of zebrafish alive three days post infection. Because 
∆CpsA is anticipated to produce less capsule and capsule is an important virulence factor, 
it is expected that GBS ∆CpsA transformants will show a decrease in virulence when 
compared to the GBS wild type transformants. Once performed, these assays will provide 
evidence that either the amino acids mutated are unique targets for the treatment of GBS 
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systemic infections by decreasing capsule production and attenuating virulence or the 
assays will indicate that new amino acids should be targeted.  
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